Efficacy and Safety of Remdesivir in Hospitalized Pediatric COVID-19: A Retrospective Case-Controlled Study

References

• Wang Z, Yang L. The therapeutic potential of natural dietary flavonoids against SARS-CoV-2 infection. Nutrients. 2023;15(15):3443. doi:10.3390/nu15153443
   PubMed Web of Science ®Google Scholar
• McIntosh K, Hirsch MS, Bogorodskaya M. COVID-19: clinical features; 2023.
   Google Scholar
• Manti S, Licari A, Montagna L, et al. SARS-CoV-2 infection in pediatric population. Acta Biomed. 2020;91(11–S):e2020003. doi:10.23750/abm.v91i11-S.10298
   PubMedGoogle Scholar
• Shakoor H, Feehan J, Al Dhaheri AS, et al. Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: could they help against COVID-19? Maturitas. 2021;143:1–9. doi:10.1016/j.maturitas.2020.08.003
   PubMed Web of Science ®Google Scholar
• Michienzi SM, Badowski ME. Can vitamins and/or supplements provide hope against coronavirus? Drugs Context. 2020;9:1–29. doi:10.7573/dic.2020-5-7
   Google Scholar
• Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health. 2020;13(10):1373–1380. doi:10.1016/j.jiph.2020.06.021
   PubMed Web of Science ®Google Scholar
• Naghipour S, Ghodousi M, Rahsepar S, Elyasi S. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine – from HIV-1 infection to COVID-19. Expert Rev Anti Infect Ther. 2020;18(11):1119–1133. doi:10.1080/14787210.2020.1792291
   PubMed Web of Science ®Google Scholar
• Pawar AY. Combating devastating COVID-19 by drug repurposing. Int J Antimicrob Agents. 2020;56(2):105984. doi:10.1016/j.ijantimicag.2020.105984
   PubMed Web of Science ®Google Scholar
• Wang J. Fast identification of possible drug treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study. J Chem Inf Model. 2020;60(6):3277–3286. doi:10.1021/acs.jcim.0c00179
   PubMed Web of Science ®Google Scholar
• McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859. doi:10.1016/j.phrs.2020.104859
   PubMed Web of Science ®Google Scholar
• Hall DC, Ji HF. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020;35:101646. doi:10.1016/j.tmaid.2020.101646
   PubMed Web of Science ®Google Scholar
• Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21–e23. doi:10.1016/j.jinf.2020.03.060
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020;253:117592. doi:10.1016/j.lfs.2020.117592
   PubMed Web of Science ®Google Scholar
• Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5). doi:10.1128/AAC.00399-20
   Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):7798):265–269. doi:10.1038/s41586-020-2008-3
   Web of Science ®Google Scholar
• Yang L, Wang Z. Bench-to-bedside: innovation of small molecule anti-SARS-CoV-2 drugs in China. Eur J Med Chem. 2023;257:115503. doi:10.1016/j.ejmech.2023.115503
   PubMed Web of Science ®Google Scholar
• Blair HA. Remdesivir: a review in COVID-19. Drugs. 2023;83(13):1215–1237. doi:10.1007/s40265-023-01926-0
   PubMed Web of Science ®Google Scholar
• Ko WC, Rolain JM, Lee NY, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020;55(4):105933. doi:10.1016/j.ijantimicag.2020.105933
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-9
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764
   PubMed Web of Science ®Google Scholar
• Linsell L, Bell J. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020;383(21):2030–2040. doi:10.1056/NEJMoa2022926
   PubMed Web of Science ®Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020:m1849. doi:10.1136/bmj.m1849
   PubMedGoogle Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. N Engl J Med. 2020;383(21):2041–2052. doi:10.1056/NEJMoa2019014
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Chan‐Tack K, Sampson M, Earp J, et al. Considerations and challenges in the remdesivir COVID‐19 pediatric development program. J Clin Pharmacol. 2023;63(2):259–265. doi:10.1002/jcph.2158
   PubMed Web of Science ®Google Scholar
• Low M, City F. EUA 046 Gilead remdesivir LOA outpatients (01212022); 2022:1–9
   Google Scholar
• FDA. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. FDA; 2020.
   Google Scholar
• Hegazy SK, Tharwat S, Hassan AH. Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients. J Clin Virol Plus. 2023;3(2):100151. doi:10.1016/j.jcvp.2023.100151
   PubMedGoogle Scholar
• WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO solidarity randomised trial and updated meta-analyses [published correction appears in Lancet. 2022 Oct 29;400(10362):1512]. Lancet. 2022;399(10339):1941–1953. doi:10.1016/S0140-6736(22)00519-0
   PubMed Web of Science ®Google Scholar
• Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a Phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22(2):209–221. doi:10.1016/S1473-3099(21)00485-0
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R; WHO Solidarity Trial Consortium. Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511. doi:10.1056/NEJMoa2023184
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang L, Song X-Q. Oral GS-441524 derivatives: next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase. Front Immunol. 2022;13:1015355. doi:10.3389/fimmu.2022.1015355
   PubMed Web of Science ®Google Scholar
• Humeniuk R, Mathias A, Kirby BJ, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor. Clin Pharmacokinet. 2021;60(5):569–583. doi:10.1007/s40262-021-00984-5
   PubMed Web of Science ®Google Scholar
• Yang K. What do we know about remdesivir drug interactions? Clin Transl Sci. 2020;13(5):842–844. doi:10.1111/cts.12815
   PubMed Web of Science ®Google Scholar
• Munoz F, Muller W, Ahmed A, et al. Safety and efficacy of remdesivir in a pediatric covid-19 population. Top Antivir Med. 2021;29(1):237.
   Google Scholar
• Elsawah HK, Elsokary MA, Abdallah MS, ElShafie AH. Efficacy and safety of remdesivir in hospitalized Covid‐19 patients: systematic review and meta‐analysis including network meta‐analysis. Rev Med Virol. 2021;31(4). doi:10.1002/rmv.2187
   PubMed Web of Science ®Google Scholar
• Wu Z, Han Z, Liu B, Shen N. Remdesivir in treating hospitalized patients with COVID-19: a renewed review of clinical trials. Front Pharmacol. 2022;13. doi:10.3389/fphar.2022.971890
   Web of Science ®Google Scholar
• Angamo MT, Mohammed MA, Peterson GM. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. Infection. 2022;50(1):27–41. doi:10.1007/s15010-021-01671-0
   PubMed Web of Science ®Google Scholar
• Seethapathy R, Wang Q, Zhao S, et al. Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function. PLoS One. 2023;18(2):e0279765. doi:10.1371/journal.pone.0279765
   PubMed Web of Science ®Google Scholar
• Alsowaida YS, Shehadeh F, Kalligeros M, Mylonakis E. Incidence, and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: a retrospective cohort study. Front Pharmacol. 2023;14:1106044. doi:10.3389/fphar.2023.1106044
   PubMed Web of Science ®Google Scholar
• Maharaj AR, Wu H, Hornik CP, et al. Simulated assessment of pharmacokinetically guided dosing for investigational treatments of pediatric patients with coronavirus disease 2019. JAMA Pediatr. 2020;174(10):e202422. doi:10.1001/jamapediatrics.2020.2422
   PubMed Web of Science ®Google Scholar
• Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc. 2021;10(1):34–48. doi:10.1093/jpids/piaa115
   PubMed Web of Science ®Google Scholar
• Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653–661. doi:10.1016/S2352-4642(20)30177-2
   PubMedGoogle Scholar
• Kim L, Whitaker M, O’Halloran A, et al. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 — COVID-NET,14 States, March 1–July 25, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1081–1088. doi:10.15585/mmwr.mm6932e3
   PubMed Web of Science ®Google Scholar
• Hasan MR, Al Zubaidi K, Diab K, et al. COVID-19 related multisystem inflammatory syndrome in children (MIS-C): a case series from a tertiary care pediatric hospital in Qatar. BMC Pediatr. 2021;21(1):267. doi:10.1186/s12887-021-02743-8
   PubMed Web of Science ®Google Scholar
• Molloy EJ, Nakra N, Gale C, Dimitriades VR, Lakshminrusimha S. Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management. Pediatr Res. 2023;93(6):1499–1508. doi:10.1038/s41390-022-02263-w
   PubMed Web of Science ®Google Scholar
• Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405–407. doi:10.1016/j.healun.2020.03.012
   PubMed Web of Science ®Google Scholar
• Goldman DL, Aldrich ML, Hagmann SHF, et al. Compassionate use of remdesivir in children with severe COVID-19. Pediatrics. 2021;147(5). doi:10.1542/peds.2020-047803
   Web of Science ®Google Scholar
• La Tessa A, Motisi MA, Marseglia GL, et al. Use of remdesivir in children with covid-19 infection: a quick narrative review. Acta Biomed. 2021;92(3). doi:10.23750/ABM.V92IS7.12396
   PubMedGoogle Scholar
• Mohammad Zadeh N, Mashinchi Asl NS, Forouharnejad K, et al. Mechanism and adverse effects of COVID-19 drugs: a basic review. Int J Physiol Pathophysiol Pharmacol. 2021;13(4):102–109.
   PubMedGoogle Scholar